Braidwell »

Castle Biosciences shares owned by Braidwell

Quarter-by-quarter ownership of Castle Biosciences (CSTL) shares owned by Braidwell from 13F filings

Historical chart of Braidwell investment in Castle Biosciences

Tip: Access up to 7 years of quarterly data

All positions including Castle Biosciences held by Braidwell consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Castle Biosciences by Braidwell

Quarter filed Position value Share count Share price at filing
2024-09-30 $9.5M 332k 28.52
2024-06-30 $9.1M 416k 21.77

More positions owned by Braidwell

Guardant Health Note11/1 (Principal)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Novocure Note11/0 (Principal)
Cg Oncology (CGON)
Nuvasive Note 0.375% 3/1 (Principal)
Xenon Pharmaceuticals (XENE)
Neurocrine Biosciences (NBIX)
Neogenomics Note 0.250% 1/1 (Principal)
Apogee Therapeutics (APGE)
Apellis Pharmaceuticals (APLS)
Ironwood Pharmaceuticals Note 1.500% 6/1 (Principal)
Dexcom Note 0.375% 5/1 (Principal)
Align Technology (ALGN)
Guardant Health (GH)
Insulet Corp Note 0.375% 9/0 (Principal)

View all positions for Braidwell

Top funds holding Castle Biosciences

BlackRock
BlackRock
Daniel D. Thurber
Vanguard Group
Principal Financial Group
Bellevue Group
Portolan Capital Management
Dimensional Fund Advisors
Soleus Capital Management
Citadel Advisors
Geode Capital Management
State Street Corporation
Palisade Capital Management
Point72 Asset Management
Jacobs Levy Equity Management

View all funds holding Castle Biosciences